Stephen Yip

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6470268/publications.pdf

Version: 2024-02-01

71102 48315 8,681 163 41 88 citations h-index g-index papers 169 169 169 15618 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas. New England Journal of Medicine, 2010, 363, 1532-1543.	27.0	1,460
2	Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nature Genetics, 2014, 46, 457-461.	21.4	423
3	The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery. Cell, 2016, 167, 1145-1149.	28.9	404
4	Distinct evolutionary trajectories of primary highâ€grade serous ovarian cancers revealed through spatial mutational profiling. Journal of Pathology, 2013, 231, 21-34.	4.5	357
5	<i>MSH6</i> Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance. Clinical Cancer Research, 2009, 15, 4622-4629.	7.0	344
6	Concurrent <i>CIC</i> mutations, <i>IDH</i> mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. Journal of Pathology, 2012, 226, 7-16.	4.5	272
7	Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurology, The, 2010, 9, 717-726.	10.2	251
8	Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma. Clinical Cancer Research, 2015, 21, 3307-3317.	7.0	230
9	Targeting Placental Growth Factor/Neuropilin 1 Pathway Inhibits Growth and Spread of Medulloblastoma. Cell, 2013, 152, 1065-1076.	28.9	209
10	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell, 2016, 30, 891-908.	16.8	191
11	Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro-Oncology, 2012, 14, 132-144.	1.2	185
12	Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathologica, 2017, 134, 705-714.	7.7	168
13	Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. Lancet Oncology, The, 2015, 16, 569-582.	10.7	147
14	Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer. Clinical Cancer Research, 2017, 23, 7521-7530.	7.0	144
15	Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nature Medicine, 2020, 26, 720-731.	30.7	141
16	ETV6-NTRK3 Is Expressed in a Subset of ALK-Negative Inflammatory Myofibroblastic Tumors. American Journal of Surgical Pathology, 2016, 40, 1051-1061.	3.7	139
17	Rise of the Machines: Advances in Deep Learning for Cancer Diagnosis. Trends in Cancer, 2019, 5, 157-169.	7.4	129
18	Disulfiram, a drug widely used to control alcoholism, suppresses self-renewal of glioblastoma and overrides resistance to temozolomide. Oncotarget, 2012, 3, 1112-1123.	1.8	123

#	Article	IF	CITATIONS
19	<i>NRG1</i> Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in <i>KRAS</i> Wild-Type Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2019, 25, 4674-4681.	7.0	121
20	The driver landscape of sporadic chordoma. Nature Communications, 2017, 8, 890.	12.8	115
21	MYCN amplification drives an aggressive form of spinal ependymoma. Acta Neuropathologica, 2019, 138, 1075-1089.	7.7	104
22	Oncolytic Virus-Mediated Manipulation of DNA Damage Responses: Synergy With Chemotherapy in Killing Glioblastoma Stem Cells. Journal of the National Cancer Institute, 2012, 104, 42-55.	6.3	103
23	Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes. Nature Cancer, 2020, 1, 452-468.	13.2	103
24	Nucleic acid quantity and quality from paraffin blocks: Defining optimal fixation, processing and DNA/RNA extraction techniques. Experimental and Molecular Pathology, 2012, 92, 33-43.	2.1	100
25	Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers. Journal of Physical Education and Sports Management, 2015, 1, a000570.	1.2	92
26	Molecular Diagnostic Testing in Malignant Gliomas: A Practical Update on Predictive Markers. Journal of Neuropathology and Experimental Neurology, 2008, 67, 1-15.	1.7	84
27	Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer. Annals of Oncology, 2017, 28, 3092-3097.	1.2	83
28	Personalizing the Treatment of Pediatric Medulloblastoma: Polo-like Kinase $1\mathrm{as}$ a Molecular Target in High-Risk Children. Cancer Research, 2013, 73, 6734-6744.	0.9	79
29	Microcystic Stromal Tumor. American Journal of Surgical Pathology, 2015, 39, 1420-1426.	3.7	78
30	Frequent expression of KIT in endometrial stromal sarcoma with YWHAE genetic rearrangement. Modern Pathology, 2014, 27, 751-757.	5.5	71
31	Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors. Oncogene, 2010, 29, 3185-3195.	5.9	69
32	Application of a Neural Network Whole Transcriptome–Based Pan-Cancer Method for Diagnosis of Primary and Metastatic Cancers. JAMA Network Open, 2019, 2, e192597.	5.9	67
33	Polo-Like Kinase 1 Inhibition Kills Glioblastoma Multiforme Brain Tumor Cells in Part Through Loss of SOX2 and Delays Tumor Progression in Mice. Stem Cells, 2012, 30, 1064-1075.	3.2	66
34	Machine learning classifies cancer. Nature, 2018, 555, 446-447.	27.8	64
35	Neural Stem Cell Biology May Be Well Suited for Improving Brain Tumor Therapies. Cancer Journal (Sudbury, Mass), 2003, 9, 189-204.	2.0	58
36	Novel targeted therapies in chordoma: an update. Therapeutics and Clinical Risk Management, 2015, 11, 873.	2.0	53

#	Article	lF	Citations
37	Synthesis of diagnostic quality cancer pathology images by generative adversarial networks. Journal of Pathology, 2020, 252, 178-188.	4.5	53
38	MOUSE SKIN PHOTOSENSITIZATION WITH BENZOPORPHYRIN DERIVATIVES AND PHOTOFRIN®: MACROSCOPIC AND MICROSCOPIC EVALUATION. Photochemistry and Photobiology, 1991, 53, 281-286.	2.5	50
39	Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 202-212.	7.0	50
40	Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. Npj Precision Oncology, 2017, 1, 5.	5.4	49
41	Neural stem cells as novel cancer therapeutic vehicles. European Journal of Cancer, 2006, 42, 1298-1308.	2.8	45
42	Loss of H3K27me3 in meningiomas. Neuro-Oncology, 2021, 23, 1282-1291.	1.2	45
43	Novel <i>EPC1</i> gene fusions in endometrial stromal sarcoma. Genes Chromosomes and Cancer, 2018, 57, 598-603.	2.8	44
44	Clinicopathologic Characterization of GREB1-rearranged Uterine Sarcomas With Variable Sex-Cord Differentiation. American Journal of Surgical Pathology, 2019, 43, 928-942.	3.7	43
45	Improved structural variant interpretation for hereditary cancer susceptibility using long-read sequencing. Genetics in Medicine, 2020, 22, 1892-1897.	2.4	42
46	The cost and cost trajectory of wholeâ€genome analysis guiding treatment of patients with advanced cancers. Molecular Genetics & mp; Genomic Medicine, 2017, 5, 251-260.	1.2	40
47	Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer. Annals of Oncology, 2016, 27, 801-806.	1.2	39
48	Interpretable multimodal deep learning for real-time pan-tissue pan-disease pathology search on social media. Modern Pathology, 2020, 33, 2169-2185.	5.5	36
49	Personalized Oncogenomics: Clinical Experience with Malignant Peritoneal Mesothelioma Using Whole Genome Sequencing. PLoS ONE, 2015, 10, e0119689.	2.5	36
50	Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity. Oncotarget, 2014, 5, 7960-7979.	1.8	35
51	Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas. BMC Cancer, 2015, 15, 32.	2.6	34
52	Base excision repair deficiency signatures implicate germline and somatic <i>MUTYH</i> aberrations in pancreatic ductal adenocarcinoma and breast cancer oncogenesis. Journal of Physical Education and Sports Management, 2019, 5, a003681.	1.2	33
53	G-quadruplexes mark alternative lengthening of telomeres. NAR Cancer, 2021, 3, zcab031.	3.1	33
54	High-resolution myelin water imaging in post-mortem multiple sclerosis spinal cord: A case report. Multiple Sclerosis Journal, 2016, 22, 1485-1489.	3.0	32

#	Article	IF	Citations
55	Transcriptomic analysis of CIC and ATXN1L reveal a functional relationship exploited by cancer. Oncogene, 2019, 38, 273-290.	5.9	32
56	Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer. Pathology and Oncology Research, 2020, 26, 1385-1399.	1.9	32
57	Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of Molecular Diagnostics, 2015, 17, 661-668.	2.8	31
58	Comparative transcriptome analysis of isogenic cell line models and primary cancers links capicua (<scp>CIC</scp>) loss to activation of the MAPK signalling cascade. Journal of Pathology, 2017, 242, 206-220.	4.5	31
59	EZH2 expression is a prognostic factor in childhood intracranial ependymoma: A Canadian Pediatric Brain Tumor Consortium study. Cancer, 2015, 121, 1499-1507.	4.1	30
60	Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non–small Cell Lung Cancer. Journal of Histochemistry and Cytochemistry, 2016, 64, 587-600.	2.5	30
61	Atypical Teratoid Rhabdoid Tumors (ATRTs): The British Columbia's Children's Hospital's Experience, 1986–2006. Brain Pathology, 2012, 22, 625-635.	4.1	29
62	Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas. Science Translational Medicine, 2021, 13, eabc0497.	12.4	29
63	Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas. BMC Cancer, 2014, 14, 982.	2.6	27
64	Spinal column chordoma: prognostic significance of clinical variables and (brachyury) gene SNP rs2305089 for local recurrence and overall survival. Neuro-Oncology, 2016, 19, now156.	1.2	27
65	Targeted RNA expression profiling identifies high-grade endometrial stromal sarcoma as a clinically relevant molecular subtype of uterine sarcoma. Modern Pathology, 2021, 34, 1008-1016.	5.5	27
66	Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients. Current Oncology, 2021, 28, 346-366.	2.2	27
67	High-grade transformation of low-grade endometrial stromal sarcomas lacking YWHAE and BCOR genetic abnormalities. Modern Pathology, 2020, 33, 1861-1870.	5.5	26
68	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. Cell Reports Medicine, 2020, 1, 100038.	6.5	24
69	Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) Low-grade Glioma Research Workshop. Neuro-Oncology, 2014, 16, 173-178.	1.2	23
70	Novel findings and expansion of phenotype in a mosaic <scp>RASopathy</scp> caused by somatic <scp><i>KRAS</i></scp> variants. American Journal of Medical Genetics, Part A, 2021, 185, 2829-2845.	1.2	23
71	Low-grade fibromyxoid sarcoma of the perineum with heterotopic ossification: case report and review of the literature. Human Pathology, 2011, 42, 1804-1809.	2.0	22
72	DNA hypermethylation and 1p Loss silence <i>NHEâ€1</i> in oligodendroglioma. Annals of Neurology, 2012, 71, 845-849.	5.3	22

#	Article	IF	CITATIONS
73	Diagnostic Value of Next-Generation Sequencing in an Unusual Sphenoid Tumor. Oncologist, 2014, 19, 623-630.	3.7	20
74	Integrative genomic analysis of ghost cell odontogenic carcinoma. Oral Oncology, 2015, 51, e71-e75.	1.5	20
75	Making heads or tails – the emergence of capicua (CIC) as an important multifunctional tumour suppressor. Journal of Pathology, 2020, 250, 532-540.	4.5	20
76	The role of resection alone in select children with intracranial ependymoma: the Canadian Pediatric Brain Tumour Consortium experience. Child's Nervous System, 2015, 31, 57-65.	1.1	19
77	Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the <scp>d</scp> â€2â€hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma. Histopathology, 2020, 76, 722-730.	2.9	19
78	The utility of color normalization for <scp>Al</scp> â€based diagnosis of hematoxylin and eosinâ€stained pathology images. Journal of Pathology, 2022, 256, 15-24.	4.5	19
79	Oncogenic codon 13 NRAS mutation in a primary mesenchymal brain neoplasm and nevus of a child with neurocutaneous melanosis. Acta Neuropathologica Communications, 2014, 2, 140.	5.2	18
80	Deep Sequencing Identifies <i>IDH1</i> R132S Mutation in Adult Medulloblastoma. Journal of Clinical Oncology, 2015, 33, e27-e31.	1.6	18
81	Personalized oncogenomic analysis of metastatic adenoid cystic carcinoma: using whole-genome sequencing to inform clinical decision-making. Journal of Physical Education and Sports Management, 2018, 4, a002626.	1.2	18
82	Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury. Npj Precision Oncology, 2021, 5, 103.	5.4	18
83	Photosensitizing Potencies of the Structural Analogues of Benzoporphyrin Derivative in Different Biological Test Systems. Photomedicine and Laser Surgery, 1996, 14, 335-341.	0.9	17
84	Differential expression and prognostic relevance of autophagy-related markers ATG4B, GABARAP, and LC3B in breast cancer. Breast Cancer Research and Treatment, 2020, 183, 525-547.	2.5	17
85	Possible differentiation of cerebral glioblastoma into pleomorphic xanthoastrocytoma: an unusual case in an infant. Journal of Neurosurgery: Pediatrics, 2012, 9, 517-523.	1.3	16
86	Molecular characterization of <i>ERBB2</i> -amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases. Journal of Physical Education and Sports Management, 2018, 4, a002535.	1.2	16
87	Converging paths to progress for skull base chordoma: Review of current therapy and future molecular targets., 2013, 4, 72.		16
88	Stem-cell based therapies for brain tumors. Current Opinion in Molecular Therapeutics, 2008, 10, 334-42.	2.8	16
89	Whole genome and whole transcriptome genomic profiling of a metastatic eccrine porocarcinoma. Npj Precision Oncology, 2018, 2, 8.	5.4	15
90	Prognostic significance of human telomerase reverse transcriptase promoter region mutations C228T and C250T for overall survival in spinal chordomas. Neuro-Oncology, 2019, 21, 1005-1015.	1.2	15

#	Article	IF	Citations
91	Fatal Congenital Hypertrophic Cardiomyopathy and a Pancreatic Nodule Morphologically Identical to Focal Lesion of Congenital Hyperinsulinism in an Infant with Costello Syndrome: Case Report and Review of the Literature. Pediatric and Developmental Pathology, 2015, 18, 237-244.	1.0	14
92	Costs of in-house genomic profiling and implications for economic evaluation: a case example of non-small cell lung cancer (NSCLC). Journal of Medical Economics, 2020, 23, 1123-1129.	2.1	14
93	Uncovering Clinically Relevant Gene Fusions with Integrated Genomic and Transcriptomic Profiling of Metastatic Cancers. Clinical Cancer Research, 2021, 27, 522-531.	7.0	14
94	MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy. Lung Cancer, 2021, 154, 142-145.	2.0	14
95	Somatic mosaicism for the p.His1047Arg mutation in PIK3CA in a girl with mesenteric lipomatosis. American Journal of Medical Genetics, Part A, 2014, 164, 2360-2364.	1.2	13
96	Detection and genomic characterization of a mammary-like adenocarcinoma. Journal of Physical Education and Sports Management, 2017, 3, a002170.	1.2	13
97	Matching methods in precision oncology: An introduction and illustrative example. Molecular Genetics & Samp; Genomic Medicine, 2021, 9, e1554.	1.2	13
98	Comparative RNA-Sequencing Analysis Benefits a Pediatric Patient With Relapsed Cancer. JCO Precision Oncology, 2018, 2, 1-16.	3.0	12
99	Therapeutic Implication of Genomic Landscape of Adult Metastatic Sarcoma. JCO Precision Oncology, 2019, 3, 1-25.	3.0	12
100	Selective elimination of malignant stem cells using photosensitizers followed by light treatment. Stem Cells, 1995, 13, 336-343.	3.2	11
101	Paternal uniparental disomy 11p15.5 in the pancreatic nodule of an infant with Costello syndrome: Shared mechanism for hyperinsulinemic hypoglycemia in neonates with Costello and Beckwith–Wiedemann syndrome and somatic loss of heterozygosity in Costello syndrome driving clonal expansion. American Journal of Medical Genetics, Part A, 2016, 170, 559-564.	1.2	11
102	Imaging-Based 3-Dimensional Printing for Improved Maxillofacial Presurgical Planning: A Single Center Case Series. Canadian Association of Radiologists Journal, 2019, 70, 74-82.	2.0	10
103	Reduced xenograft rejection in rat striatum after pretransplant photodynamic therapy of murine neural xenografts. Journal of Neurosurgery, 2000, 92, 127-131.	1.6	9
104	The impact of brain invasion criteria on the incidence and distribution of WHO grade 1, 2, and 3 meningiomas. Neuro-Oncology, 2022, 24, 1524-1532.	1.2	9
105	Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline <i>CHEK2</i> :c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma. Journal of Physical Education and Sports Management, 2017, 3, a001628.	1.2	8
106	Deep-learning based classification distinguishes sarcomatoid malignant mesotheliomas from benign spindle cell mesothelial proliferations. Modern Pathology, 2021, 34, 2028-2035.	5.5	8
107	Clinical and cost outcomes following genomicsâ€informed treatment for advanced cancers. Cancer Medicine, 2021, 10, 5131-5140.	2.8	8
108	Finding a four-leaf cloverâ€"identifying long-term survivors in IDH-wildtype glioblastoma. Neuro-Oncology, 2019, 21, 1352-1353.	1.2	7

#	Article	IF	Citations
109	TRIM25 promotes Capicua degradation independently of ERK in the absence of ATXN1L. BMC Biology, 2020, 18, 154.	3.8	7
110	A platform for oncogenomic reporting and interpretation. Nature Communications, 2022, 13, 756.	12.8	7
111	Establishing a Framework for the Clinical Translation of Germline Findings in Precision Oncology. JNCI Cancer Spectrum, 2020, 4, pkaa045.	2.9	6
112	Array CGH in Brain Tumors. Methods in Molecular Biology, 2013, 973, 325-338.	0.9	5
113	Ependymoma and Chordoma. Neurosurgery, 2020, 87, 860-870.	1.1	5
114	EGFR circulating tumour DNA testing: identification of predictors of ctDNA detection and implications for survival outcomes. Translational Lung Cancer Research, 2020, 9, 1084-1092.	2.8	5
115	Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic DPYD structural variant. Journal of Physical Education and Sports Management, 2020, 6, a004713.	1.2	5
116	The pivotal role of sampling recurrent tumors in the precision care of patients with tumors of the central nervous system. Journal of Physical Education and Sports Management, 2019, 5, a004143.	1.2	4
117	Epstein-Barr virus associated primary intracranial leiomyoma in a patient with human immunodeficiency virus., 2017, 36, 151-153.		4
118	Early-stage economic analysis of research-based comprehensive genomic sequencing for advanced cancer care. Journal of Community Genetics, 2022, 13, 523-538.	1.2	4
119	Integrated proteomic analysis of low-grade gliomas reveals contributions of 1p-19q co-deletion to oligodendroglioma. Acta Neuropathologica Communications, 2022, 10, 70.	5.2	4
120	Exceptional response to combination ipilimumab and nivolumab in metastatic uveal melanoma: Insights from genomic analysis. Melanoma Research, O, Publish Ahead of Print, .	1.2	4
121	Clinical outcomes after whole-genome sequencing in patients with metastatic non-small-cell lung cancer. Journal of Physical Education and Sports Management, 2019, 5, a002659.	1.2	3
122	NTRK2 Fusion driven pediatric glioblastoma: Identification of oncogenic Drivers via integrative Genome and transcriptome profiling. Clinical Case Reports (discontinued), 2021, 9, 1472-1477.	0.5	3
123	Survival and Recurrence Outcomes Following Adjuvant Radiotherapy for Grade 2 Intracranial Meningiomas: 13-Year Experience in a Tertiary-Care Center. World Neurosurgery, 2022, , .	1.3	3
124	The impact of whole genome and transcriptome analysis (<scp>WGTA</scp>) on predictive biomarker discovery and diagnostic accuracy of advanced malignancies. Journal of Pathology: Clinical Research, 2022, 8, 395-407.	3.0	3
125	Letter to the Editor: Cribriform neuroepithelial tumor or atypical teratoid/rhabdoid tumor?. Journal of Neurosurgery: Pediatrics, 2013, 11, 486-488.	1.3	2
126	Case of Primary Central Nervous System Lymphoma Arising at Site of Remote Herpes Encephalitis. World Neurosurgery, 2018, 113, 217-222.	1.3	2

#	Article	IF	CITATIONS
127	Pathology of Primary Brain Tumors—Gliomas. , 2019, , 121-137.		2
128	Optimizing molecular residual disease detection using liquid biopsy postoperatively in early stage lung cancer. Lung Cancer Management, 2020, 9, LMT24.	1.5	2
129	Histologic Correlates of Molecular Group 4 Pediatric Medulloblastoma: A Retrospective Canadian Review. Pediatric and Developmental Pathology, 2021, 24, 309-317.	1.0	2
130	OUP accepted manuscript. American Journal of Clinical Pathology, 2022, , .	0.7	2
131	Radiation Induced Abscopal Effect in a Patient With Malignant Pleural Mesothelioma on Pembrolizumab. Cureus, 2022, 14, e22159.	0.5	2
132	The Clinically Actionable Molecular Profile of Early versus Late-Stage Non-Small Cell Lung Cancer, an Individual Age and Sex Propensity-Matched Pair Analysis. Current Oncology, 2022, 29, 2630-2643.	2.2	2
133	Characterizing the <i>KRAS</i> G12C mutation in metastatic colorectal cancer: a population-based cohort and assessment of expression differences in The Cancer Genome Atlas. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210979.	3.2	2
134	Temporal Dynamics of Genomic Alterations in a BRCA1 Germline–Mutated Pancreatic Cancer With Low Genomic Instability Burden but Exceptional Response to Fluorouracil, Oxaliplatin, Leucovorin, and Irinotecan. JCO Precision Oncology, 2018, 2, 1-8.	3.0	1
135	Perivenular Enhancement Without Microbleeds Due to Amyloid Beta-Related Angiitis. Neurohospitalist, The, 2021, 11, 267-269.	0.8	1
136	A case series of pediatric survivors of anaplastic pleomorphic xanthoastrocytoma. Neuro-Oncology Advances, 2021, 3, vdaa176.	0.7	1
137	Integrating Tumor Sequencing Into Clinical Practice for Patients With Mismatch Repair-Deficient Lynch Syndrome Spectrum Cancers. Clinical and Translational Gastroenterology, 2021, 12, e00397.	2.5	1
138	Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations Journal of Clinical Oncology, 2019, 37, e15753-e15753.	1.6	1
139	Abstract B81: Gene expression analysis demonstrates prognostic subtypes in metastatic pancreatic ductal adenocarcinoma (PDAC). Cancer Research, 2016, 76, B81-B81.	0.9	1
140	Whole genome and transcriptome sequencing of lung cancer: Options for personalized cancer treatment Journal of Clinical Oncology, 2017, 35, e20567-e20567.	1.6	1
141	35â€Yearâ€Old Man with Lytic Skull Lesion. Brain Pathology, 2015, 25, 367-368.	4.1	O
142	Oligodendroglial Tumors. Molecular Pathology Library, 2015, , 105-120.	0.1	0
143	CSIG-12. EXPLORING THE FUNCTIONAL RELATIONSHIP BETWEEN CAPICUA (CIC) AND ATAXIN-1-LIKE (ATXN1L) IN GLIOMA. Neuro-Oncology, 2017, 19, vi52-vi52.	1.2	O
144	176 Malignant Primary Spinal Column Tumors. Neurosurgery, 2018, 65, 107.	1.1	0

#	Article	IF	Citations
145	Commentary: Radiological Characteristics and Natural History of Adult IDH-Wild-Type Astrocytomas With TERT Promoter Mutations. Neurosurgery, 2019, 85, E457-E458.	1.1	0
146	Beyond BRCA? clinical utility of homologous recombination deficiency in gastrointestinal cancers Journal of Clinical Oncology, 2021, 39, 472-472.	1.6	0
147	Haplotype-resolved germline structural variation underlying male breast cancer predisposition syndromes. Molecular Genetics and Metabolism, 2021, 132, S247.	1.1	0
148	RARE-15. THE MOLECULAR PROFILE OF SECONDARY MENINGIOMAS IN SURVIVORS OF CHILDHOOD NON-CENTRAL NERVOUS SYSTEM CANCERS. Neuro-Oncology, 2021, 23, i43-i44.	1.2	0
149	Abstract 5340: Bioinformatic analyses approaches for personalized oncogenomics. , 2014, , .		0
150	Abstract 4704: Prognostic significance of T gene SNP s2305089 in individuals with spinal column chordoma. , 2014, , .		0
151	Abstract 1122: Personalized oncogenomics in advanced stage breast cancer. , 2015, , .		0
152	Abstract PR02: Integrated genomic analysis of a recurrent ghost cell odontogenic carcinoma. , 2016, , .		0
153	Abstract 2631: Restrictions on access to systemic therapy limit the application of whole genome sequencing in clinical care., 2016,,.		0
154	Abstract 5226: Genomic analysis of pancreatic ductal adenocarcinoma in a patient with MUTYH-associated polyposis. , 2016, , .		0
155	Management of germline findings revealed throughout the course of tumor-normal whole genome sequencing in oncology Journal of Clinical Oncology, 2017, 35, e13113-e13113.	1.6	0
156	Abstract 2473: Breast cancer whole genomes link homologous recombination deficiency (HRD) with the rapeutic outcomes. , 2017 , , .		0
157	Abstract A190: Management of germline findings revealed throughout the course of tumor-normal whole genome sequencing in oncology. , 2018, , .		0
158	Abstract A184: Clinical application of whole genome and transcriptome sequencing in cancer care. , 2018, , .		0
159	Abstract 4340: Integrating whole genome and transcriptome analysis to inform treatment decisions in the metastatic cancer clinical setting. , 2018 , , .		0
160	Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations Journal of Clinical Oncology, 2019, 37, 273-273.	1.6	0
161	The whole genome landscape of adult metastatic sarcoma Journal of Clinical Oncology, 2019, 37, 3137-3137.	1.6	0
162	Confirmation of germline variants identified by tumor testing: A population-based study Journal of Clinical Oncology, 2019, 37, e13021-e13021.	1.6	0

#	Article	IF	CITATIONS
163	Protracted clinical course of an AFF1 fusion positive uterine smooth muscle tumor causing diagnostic confusion over a course of 15Âyears. Gynecologic Oncology Reports, 2021, 38, 100890.	0.6	0